Imaging for early stage breast cancer

Clinical studies

Author year N Treatment

Cancer site

Endpoint

Rando- mized

Blinded Effect

Delanian S 1999 Delainan S 2003 Delanian S 2005 Futran ND 1997 Gothard L 2004 Jacobson G 2013

43 Pentox. 400 mg x 3 Vit. E 500 IU x 2 22 Pentox. 400 mg x 2 Vit. E 500 IU x 2 44 Pentox. 400 mg x 2 Vit. E 500 IU x 2 68 Pentox. 400 mg x 2 Vit. E 500 IU x 2 53 Pentox. 400 mg x 2 Vit. E 500 IU x 1 83 Pentox. 400 mg x 2 Vit. E 100 mg x 1

Breast H&N

Fibrosis area, LEND- SOMA , pain Fibrosis area, LEND- SOMA , pain Fibrosis area, LEND- SOMA , pain

No

No

Yes

Breast

Yes

Yes

No

Breast

No

No

Yes

26 Pentox. 400 mg x 3 Mixed

Mixed

No

No

Yes

Breast

Oedema, induration

Yes

Yes

No

Breast

Tissue compliance meter meassurement Arm oedema, sholder movement

Yes

No

Yes

Magnusson M 2009

Breast

Yes

Yes

yes

Okunieff P 2004

27 Pentox. 400 mg x 3 Mixed

Mixed

No

No

Yes

Adapted fromWestbury and Yarnold 2012